CA3100848A1 - Methods for improving neurological diseases and disorders - Google Patents
Methods for improving neurological diseases and disorders Download PDFInfo
- Publication number
- CA3100848A1 CA3100848A1 CA3100848A CA3100848A CA3100848A1 CA 3100848 A1 CA3100848 A1 CA 3100848A1 CA 3100848 A CA3100848 A CA 3100848A CA 3100848 A CA3100848 A CA 3100848A CA 3100848 A1 CA3100848 A1 CA 3100848A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- neurodegenerative disease
- disease
- cognitive function
- pabra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685249P | 2018-06-14 | 2018-06-14 | |
| US201862685246P | 2018-06-14 | 2018-06-14 | |
| US201862685247P | 2018-06-14 | 2018-06-14 | |
| US62/685,246 | 2018-06-14 | ||
| US62/685,247 | 2018-06-14 | ||
| US62/685,249 | 2018-06-14 | ||
| US201862686660P | 2018-06-18 | 2018-06-18 | |
| US201862686663P | 2018-06-18 | 2018-06-18 | |
| US201862686658P | 2018-06-18 | 2018-06-18 | |
| US62/686,663 | 2018-06-18 | ||
| US62/686,658 | 2018-06-18 | ||
| US62/686,660 | 2018-06-18 | ||
| US201962825670P | 2019-03-28 | 2019-03-28 | |
| US201962825702P | 2019-03-28 | 2019-03-28 | |
| US201962825571P | 2019-03-28 | 2019-03-28 | |
| US201962825675P | 2019-03-28 | 2019-03-28 | |
| US62/825,571 | 2019-03-28 | ||
| US62/825,670 | 2019-03-28 | ||
| US62/825,675 | 2019-03-28 | ||
| US62/825,702 | 2019-03-28 | ||
| PCT/US2019/037358 WO2019241736A1 (en) | 2018-06-14 | 2019-06-14 | Methods for improving neurological diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3100848A1 true CA3100848A1 (en) | 2019-12-19 |
Family
ID=68842342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3100848A Pending CA3100848A1 (en) | 2018-06-14 | 2019-06-14 | Methods for improving neurological diseases and disorders |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3806847A4 (https=) |
| JP (1) | JP2021527711A (https=) |
| AU (1) | AU2019287771A1 (https=) |
| CA (1) | CA3100848A1 (https=) |
| WO (1) | WO2019241736A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4208159A4 (en) * | 2020-09-01 | 2024-09-25 | Curasen Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE RELIEF OF NEUROLOGICAL CONDITIONS AND DISORDERS |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202302225D0 (en) | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
| GB202303229D0 (en) | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| GB202403169D0 (en) | 2024-03-05 | 2024-04-17 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
| US20040248984A1 (en) * | 2001-08-29 | 2004-12-09 | Josef Krieglstein | Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases |
| WO2011133226A2 (en) * | 2010-04-22 | 2011-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same |
| US9265735B2 (en) * | 2010-11-30 | 2016-02-23 | New York University | Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof |
| US9320724B2 (en) * | 2013-02-13 | 2016-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor |
| KR20160026897A (ko) * | 2013-06-27 | 2016-03-09 | 세다르스-신나이 메디칼 센터 | 신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제 |
-
2019
- 2019-06-14 WO PCT/US2019/037358 patent/WO2019241736A1/en not_active Ceased
- 2019-06-14 CA CA3100848A patent/CA3100848A1/en active Pending
- 2019-06-14 EP EP19819477.1A patent/EP3806847A4/en not_active Withdrawn
- 2019-06-14 JP JP2021519528A patent/JP2021527711A/ja active Pending
- 2019-06-14 AU AU2019287771A patent/AU2019287771A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3806847A1 (en) | 2021-04-21 |
| EP3806847A4 (en) | 2022-05-04 |
| WO2019241736A1 (en) | 2019-12-19 |
| AU2019287771A1 (en) | 2021-01-28 |
| JP2021527711A (ja) | 2021-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12558325B2 (en) | Methods for improving neurological diseases and disorders | |
| CA3100697A1 (en) | Methods for diagnosing, monitoring and treating neurological diseases and disorders | |
| CA3100848A1 (en) | Methods for improving neurological diseases and disorders | |
| JP5733715B2 (ja) | 経鼻中枢神経系組織標識用組成物、経鼻中枢神経系組織標識用組成物を用いた標識方法及びスクリーニング方法 | |
| US20230263749A1 (en) | Compositions and methods for improving neurological diseases and disorders | |
| WO2009005509A1 (en) | Near infrared-fluorescence using phospholipid ether analog dyes in endoscopic applications | |
| ES2750839T3 (es) | Composición farmacéutica para la prevención, tratamiento o retraso de la enfermedad de Alzheimer o demencia que contiene agente receptor acoplado a proteína G 19 como ingrediente activo | |
| US20250134835A1 (en) | Compositions and methods for treating patients with amyotrophic lateral sclerosis (als) | |
| US20210251923A1 (en) | Methods for improving neurological diseases and disorders | |
| US20230157974A1 (en) | Compositions and methods for improving neurological diseases and disorders | |
| US20230097883A1 (en) | Ergothioneine pet compounds and methods of use thereof | |
| Zhang et al. | Cholecystokinin B receptor agonists alleviates anterograde amnesia in CCK-deficient and aged Alzheimer's disease mice | |
| US7081238B2 (en) | Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level | |
| WO2024137478A1 (en) | Methods for treating various conditions and indications with agonists and antagonists | |
| WO2025188807A1 (en) | Combination compositions and methods of use | |
| CN116801875A (zh) | 用于改善神经疾病和病症的组合物和方法 | |
| Micou et al. | High-speed optical mapping of heart and brain voltage activities in zebrafish larvae exposed to environmental contaminants | |
| KR20170138437A (ko) | 신경질환 치료용 푸마레이트를 정맥투여하는 방법 및 조성물 | |
| WO2024137506A1 (en) | Compositions and methods for improving neurological diseases and disorders | |
| ES2832549T3 (es) | Composiciones y métodos para tratar la esclerosis lateral amiotrófica en respondedores | |
| Leuzy | In Vivo Quantification of Glutamatergic Abnormalities in Behavioral Variant Frontotemporal Dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220822 |